BCDA

Bullish

BioCardia's High-Stakes Gambit: A Japan-First Strategy for Heart Therapy

BioCardia is strategically prioritizing the Japanese market for its CardiAMP Cell Therapy, aiming for a Q4 2026 submission to Japan's PMDA. This "Japa...

BriefGlance 6 days ago 0

Bearish

BioCardia Disclosed Failure to Satisfy a Continued Listing Rule or Standard

BioCardia (BCDA) received a Nasdaq notice on April 10, 2026, for falling below the $2.5 million minimum stockholders' equity rule. Nasdaq granted an e...

TradingView 1 week ago 0

Neutral

BioCardia (NASDAQ: BCDA) raises $4.9M and updates Nasdaq listing compliance

BioCardia Inc. has raised $4.9 million by selling 4,004,330 shares of common stock through an "at-the-market" offering, aiming to regain compliance wi...

Stock Titan 1 week ago 0